Stimulation of platelets with thrombin leads to rapid degradation of inositol phospholipids, generation of diacylglycerol (DAG) and subsequent activation of protein kinase C (PKC). Previous studies indicated that prior activation of PKC with phorbol myristate acetate (PMA) desensitizes platelets to thrombin stimulation, as indicated by a decreased production of inositol phosphates and decreased Ca2+ mobilization. This suggests that PKC activation generates negative-feedback signals, which limit the phosphoinositide response. To test this hypothesis further, we examined the effects of PKC activators and inhibitors on thrombin-stimulated DAG mass formation in platelets. Pretreatment with PMA abolishes thrombin-stimulated DAG formation (50 % inhibition at 60 nM). Pretreatment of platelets with the PKC inhibitors K252a or staurosporine potentiates DAG production in response to thrombin (3-4-fold) when using concentrations required to infhibit platelet PKC (1-10 /LM). K252a does not inhibit phosphorylation of endogenous DAG or phosphorylation of a cell-permeant DAG in unstimulated platelets, indicating that DAG over-production is not due to inhibition of DAG kinase. Sphingosine, a PKC inhibitor with a different mechanism of action, also potentiates DAG formation in response to thrombin. Several lines of evidence indicate that DAG formation under the conditions employed occurs predominantly by phosphoinositide (and not phosphatidylcholine) hydrolysis: (1) PMA alone does not elicit DAG formation, but inhibits agonist-stimulated DAG formation; (2) thrombin-stimulated DAG formation is inhibited by neomycin (1-10 mM) but not by the phosphatidate phosphohydrolase inhibitor propranolol; and (3) no metabolism of radiolabelled phosphatidylcholine was observed upon stimulation by thrombin or PMA. These data provide strong support for a role of PKC in limiting the extent of platelet phosphoinositide hydrolysis.
INTRODUCTION
The primary event following binding of many extracellular agonists to their specific receptors is the hydrolysis of membrane phospholipids. The best-characterized pathway of phospholipid hydrolysis is the cleavage of the phosphoinositides phosphatidylinositol 4,5-bisphosphate (PtdInsP2), phosphatidylinositol 4-phosphate and phosphatidylinositol (Ptdlns) by a phospholipase C (PLC) mechanism (reviewed by Majerus et al., 1986) . PtdInsP2 breakdown generates two second messengers: (i) inositol 1,4,5-trisphosphate (InsP3), which mobilizes Ca2+ from intracellular stores; and (ii) sn-1,2-diacylglycerol (DAG), which remains membrane-associated and activates protein kinase C (PKC). Coupling of receptors to phosphoinositide-specific PLC appears to be mediated by a guanine-nucleotide-binding protein (G-protein) .
There is considerable evidence that treatment of cells with phorbol esters inhibits subsequent phosphoinositide hydrolysis. For example, pretreatment with phorbol myristate acetate (PMA) blocks chemotactic-peptide-and guanosine 5'-[y-thio]-triphosphate-induced InsP3 formation in plasma membranes from human polymorphonuclear leucocytes (Smith et al., 1987) and in HL60 cells (Kikuchi et al., 1987) and guanosine 5'-[ythioltriphosphate-plus-carbachol-induced InsP3 formation in astrocytoma membranes (Orellana et al., 1987) . In all cases, PMA does not affect the ability of Ca2+ to activate PtdInsP2 hydrolysis. Similarly, PMA blocks Ca2+ mobilization and InsP3 production in hepatocytes stimulated with Ca2+-mobilizing hormones or AIF4-(to activate the coupling G-protein directly) (Blackmore & Exton, 1986) . These observations led to the hypothesis that activation of PKC limits the phosphoinositide response by inhibiting the coupling of the G-protein to phosphoinositide-specific PLC. Considerable work has been done on phosphoinositide turnover in thrombin-stimulated platelets. Hydrolysis of PtdInsP2 is one of the earliest events on treatment of platelets with thrombin (Billah & Lapetina, 1982) . PtdInsP2 mass decreases transiently upon thrombin stimulation, reaching a minimum at 20 s and then returning to basal levels (Wilson et al., 1985) . A larger decrease in Ptdlns mass is observed over the course of 90 s (Wilson et al., 1985) . Phosphoinositide hydrolysis is accompanied by accumulation of inositol phosphates. InsP3 accumulation is transient; within 15 s InsP3 levels reach 134 pmol/109 platelets, but then fall rapidly back towards basal levels by 2 min (Rittenhouse & Sasson, 1985) . The other product of the PLC reaction, DAG, also accumulates transiently. DAG mass reaches a peak at 30 s (at 250-300 pmol/109 platelets), followed by a rapid decrease to basal levels (75-100 pmol/101 platelets) (Preiss et al., 1986; . The pathways for rapid attenuation of these second messengers have been investigated extensively (reviewed by Majerus et al., 1986; Bishop & Bell, 1988) . PMA pretreatment also prevents phosphoinositide hydrolysis in platelets. PMA blocks thrombin-induced InsP3 formation (Rittenhouse & Sasson, 1985; Watson & Lapetina, 1985) and Ca2+ mobilization (Zavoico et al., 1985) , consistent with a negative-feedback role for PKC in this system.
The objective of the present work was to test further the hypothesis that PKC activation limits the phosphoinositide Vol. 269 Abbreviations used: DAG, diacylglycerol; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; PC, phosphatidylcholine; PA, phosphatidic acid; PLC, phospholipase C; diC8, sn-1,2-dioctanoylglycerol; DMSO, dimethyl sulphoxide; IC50, concn. giving 50% inhibition.
* To whom correspondence and reprint requests should be addressed. response in platelets, by examining the effects of PKC activators and inhibitors on DAG formation. We found that phorbol ester pretreatment blocks DAG formation. In addition, PKC inhibitors of two classes, the catalytic-domain inhibitors K252a and staurosporine (Tamaoki et al., 1986) , and sphingosine, a regulatory-domain inhibitor (Hannun et al., 1986) , both cause dramatic over-production of DAG second messengers over the concentration range required for inhibition of other PKC actions.
Interpretation of these results is complicated by previous demonstrations that DAG formation also occurs by degradation of phosphatidylcholine (PC) in agonist-stimulated cells. PC hydrolysis to DAG may occur by two mechanisms. Evidence for a PLC mechanism (generating DAG and phosphocholine) has been provided in several systems (Daniel et al., 1986; Besterman et al., 1986; Irving & Exton, 1987; Muir & Murray, 1987; Takuwa et al., 1987; . Alternatively, PC hydrolysis can occur by the action ofphospholipase D, generating choline and phosphatidic acid (PA). PA is subsequently hydrolysed by PA phosphohydrolase, yielding DAG (Bocckino et al., 1987; Pai et al., 1988a,b; Billah et al., 1989b) . The mechanism by which PC hydrolysis is initiated in these various systems remains to be established; however, PC hydrolysis by either pathway can be initiated by phorbol ester treatment (see e.g. Daniel et al., 1986; Billah et al., 1989a) .
To clarify the interpretation of our data, it was necessary to define the contribution of phosphoinositide and PC turnover to total DAG formation under our experimental conditions. Several approaches were taken, including: (i) examination of the effects of neomycin, a compound reported to inhibit PLC by interaction with the inositol phospholipid substrate (e.g. , and of propranolol, an inhibitor of PA phosphohydrolase (e.g. Abdel-Latif & Smith, 1976; Eichberg et al., 1979) ; (ii) examination of the effects of phorbol ester treatment; and (iii) direct examination of the turnover of radiolabelled PC. The results are consistent with phosphoinositide turnover being the primary source of DAG in stimulated platelets.
EXPERIMENTAL Materials
K252a and staurosporine were purchased from Kyowa Hakko U.S.A. Inc. (New York, NY, U.S.A.). D-erythro-Sphingosine, prostaglandin 12, thrombin (from human plasma), neomycin sulphate, DL-propranolol and PMA were from Sigma. The DAG kinase inhibitor R59022 was from Calbiochem. sn-1 ,2-Dioctanoylglycerol (diC8) was obtained from Avanti Polar Lipids Inc. (Birmingham, AL, U.S.A.).
Escherichia coli DAG kinase was prepared as described previously (Preiss et al., 1986) 
Preparation and labelling of human platelets
Human platelets were prepared from freshly drawn blood essentially as described by Siess et al. (1983) . Platelets were resuspended at 6.25 x 108/ml in modified Tyrode-Hepes medium (134 mM-NaCl, 12 mM-NaHCO3, 2.9 mM-KCI, 0.34 mM-Na-H2P04, mM-MgCI2, 5 mM-Hepes, S mM-glucose, 1 mM-EGTA, Unlabelled platelets (6.25 x 108/ml) were pretreated as described in the Results section before stimulation with a maximal dose of thrombin (1 unit/ml). For measurement of platelet DAG mass, a 0.8 ml sample containing 5 x 108 platelets was extracted at the indicated time, and DAG present in the final chloroform phase was measured by using E. coli DAG kinase essentially as described previously Preiss et al., 1986) Control experiments demonstrated that all inhibitors used for platelet pretreatments do not significantly inhibit the E. coli DAG kinase (results not shown). Inhibitors were used at the maximum concentration that they would achieve in the DAG kinase reaction assuming 100% recovery in the platelet lipid extracts: 1.2 gM-PMA, 50 uM-K252a and -staurosporine, 400 /sM-propranolol, I mM-sphingosine and 45 mM-neomycin sulphate.
PA formation 32P-labelled platelets were subjected to various pre-treatments as described in the Results section. When phosphorylation of diC8 was measured, 25 ,M-diC8 (in ethanol) was added immediately before thrombin stimulation. Samples (0.1 ml) containing 6.25 x 107 platelets were extracted at the indicated time, and long-chain endogenous [32P]PA and [32P]diC8 PA were separated by t.l.c. as described previously SDS/10 %-polyacrylamide gels. Gels were fixed, dried and autoradiographed as previously described Some 22 % of the cell-associated label was in PC, less than 2 % was in other phospholipid species, and the remainder was recovered as non-esterified fatty acid. Platelets were stimulated with thrombin (1 unit/ml) or PMA (100 nM) alone or in the presence of 0.5 % ethanol. Samples (0.5 ml) containing 3 x 108 platelets (approx. 50000 c.p.m. of [3H]PC) were extracted, and the chloroform phase was analysed by t.l.c. For separation of PA and phosphatidylethanol, the solvent system used was the organic phase from a mixture of ethyl acetate/iso-octane/water/acetic acid (I 11:5: 10: 2, by vol).
RESULTS

Phorbol ester pretreatment blocks thrombin-stimulated DAG formation
Upon stimulation of platelets with a maximal dose of thrombin, DAG formation occurs rapidly, reaching a peak at 3.5 times the resting DAG mass level at 0.5 min, then rapidly returning to basal levels by 5 min after thrombin addition (Fig. 1) . Other biochemical and physiological responses of platelets (e.g. phosphorylation of the 40 kDa PKC substrate and 5-hydroxytryptamine secretion) are also maximal by 0.5-1 min after stimulation with this dose of thrombin.
Activation of platelet PKC with PMA does not affect platelet DAG mass levels ( Fig. 1) . No increase in DAG mass was seen for 30 min after addition of PMA from 50 to 500 nm.
Pretreatment of platelets with phorbol ester for 5 min abolishes the thrombin-induced rise in DAG mass (Fig. 1) . The PMA dose/response curve is shown in Fig. 2 (Rittenhouse & Sasson, 1985 .
PKC activation is thought to be an essential step in the signaltransduction pathway leading to the physiological responses of platelets (see, e.g., Hannun et al., 1987) . As reported previously , inhibition of PKC by K252a blocks phosphorylation of the 40 kDa PKC substrate [IC50 (concn.
giving 500% inhibition) = 2.1 /LM] and prevents 5-hydroxytryptamine secretion (IC50 = 1.2 /tM) in thrombin-stimulated platelets (Fig. 3) . Inhibition of secretion is complete after a 1 min preincubation with 10 1M-K252a.
When platelets are pretreated with 10,uM-K252a for 1 min before thrombin stimulation, a much greater DAG response is observed (Fig. 4) . In control platelets, thrombin induces a 3.5-fold increase in DAG levels (from 36.2 to a maximum of 122.8 pmol/5 x 108 platelets at 0.5 min in one experiment). In the presence of 10 M-K252a, maximal DAG levels achieved were 10-fold higher than resting levels (361.7 pmol/5 x 108 platelets) (Fig. 4) .
To rule out an effect of K252a on DAG phosphorylation, we measured the rate of 32P labelling of PA after thrombin stimulation. Pretreatment of platelets for I min with 10 /tM-K252a before thrombin stimulation enhanced incorporation of 32P into PA approx. 2-fold (Fig. 5) . This result is consistent with an increased flux through DAG and provides evidence that DAG kinase is not inhibited.
The ability of platelet DAG kinase to phosphorylate an exogenous cell-permeant DAG, diC8, was also examined. The rate of diC8 phosphorylation is unaffected by prior treatment with 10 /tM-K252a (Fig. 6a) . Staurosporine (10 #M) also did not , 1985) , decreases the rate of diC8 phosphorylation by approx. 50 %.
A similar experiment was also performed in thrombin-stimulated platelets (Fig. 6b) . Thrombin stimulation does not alter the rate of diC8 phosphorylation. However, 10 ,/M-K252a slows the rate of diC8 phosphorylation in stimulated platelets. A more pronounced effect on diC8 phosphorylation was observed with R59022. The decreased rate of diC8 phosphorylation in the presence of K252a may be due to elevated endogenous DAG competing with diC8 for DAG kinase (e.g. MacDonald et al., 1988a,b).
Sphingosine potentiates thrombin-stimulated DAG formation
The above results suggest that DAG over-production in the presence of K252a was due to enhanced DAG formation and not to a decreased rate of DAG metabolism. To support this further, we examined the effect of another PKC inhibitor, sphingosine, on DAG formation. Unlike K252a and staurosporine, sphingosine inhibits PKC by interacting with the regulatory lipidbinding domain (Hannun et al., 1986) ; therefore interaction of sphingosine with the ATP site of DAG kinase would be unlikely.
Pretreatment of platelets for 1 min with concentrations of sphingosine required to inhibit PKC-mediated events in response to thrombin (i.e. 10-25 4uM) (Hannun et al., 1986 (Hannun et al., , 1987 results in enhanced DAG formation upon thrombin stimulation (Fig. 7) . In the experiment shown in Fig. 7 , peak DAG levels achieved in response tc thrombin were 118 pmol/5 x 108 platelets in control platelets, 206 in the presence of 12.5 ,uM-sphingosine and 275 in the presence of 25 4uM-sphingosine.
Similar results were seen with 50,uM-sphingosine; however, higher concentrations result in less DAG over-production (Table  2) . Thrombin-stimulated DAG levels reached a peak at 150 pmol/5 x 108 cells with 100 ,uM-sphingosine; 200,MMsphingosine nearly abolished thrombin-stimulated DAG formation, and slightly decreased basal (resting) DAG levels ( The above results are consistent with a role for PKC in limiting phosphoinositide hydrolysis in thrombin-stimulated platelets. However, it is clear that in many cell types hydrolysis of other phospholipids (primarily PC) contributes to DAG production. Two approaches were used to examine the possible contribution of PC hydrolysis under our experimental conditions. First, cellular PC pools were prelabelled by several methods. Attempts to label platelet PC by preincubation with [3H]1-Oalkyl-2-lyso-PC (Pai et al., 1988a,b) The effects of available inhibitors of phospholipid hydrolytic pathways were also examined. Neomycin has been reported to inhibit phosphoinositide hydrolysis in thrombin-stimulated plate- lets. Neomycin sulphate completely inhibits the thrombininduced rise in DAG mass (IC50 = 2.8 mM) (Table 3) . Maximal inhibition was achieved after a 5 min preincubation with 10 mMneomycin. This is the same concentration range required to prevent phosphoinositide hydrolysis (Tysnes et al., 1988) , and is consistent with phosphoinositide hydrolysis being the primary source of DAG in these experiments. In control experiments, where 10 mM-neomycin sulphate completely inhibited the thrombin response, 30 mM-Na2SO4 decreased the response by 34 %.
This suggests that, although some of the decreased DAG response may be due to the high concentrations of sulphate present, most of the inhibition is mediated by neomycin. Propranolol has been reported to inhibit PA phosphohydrolase; therefore this compound should prevent DAG formation by the phospholipase D pathway. Pretreatment of platelets with propranolol at concentrations up to 200 /M does not inhibit DAG formation induced by thrombin (Table 3) . In fact, treatment with 200,uM-propranolol enhances DAG formation (1.6-2.7-fold) after thrombin stimulation, whereas propranolol alone does not elevate platelet DAG levels. The mechanism of the potentiating effect of propranolol requires further investigation.
DISCUSSION
Phosphoinositide turnover is the primary source of DAG in thrombin-stimulated platelets
To understand the observed effects of PKC inhibitors on DAG mass levels, it was necessary to examine the pathways by which activated platelets generate DAG. Several lines of evidence indicate that phosphoinositide hydrolysis is the predominant source of DAG under the conditions used.
(i) Activation of PKC by phorbol esters induces PC hydrolysis (e.g. Billah et al., 1989a) and subsequently DAG formation (e.g. Rider et al., 1988) in a number of cell types. In contrast, phorbol ester treatment blocks agonist-stimulated phosphoinositide hydrolysis. In human platelets, phorbol esters alone did not induce DAG formation. In neutrophils, where PMA activates 300 200 E (9 0 PC-hydrolytic pathways, DAG mass formation is observed by 1 min and is maximal by about 30 min after PMA addition (Rider et al., 1988) . In addition, pretreatment of platelets with PMA blocked subsequent thrombin-stimulated DAG formation.
(ii) The putative PLC inhibitor neomycin abolishes thrombininduced DAG formation over the concentration range needed to suppress platelet phosphoinositide turnover and aggregation in response to thrombin (Tysnes et al., 1988 ). Neomycin appears to inhibit PLC activity by interacting with the phosphoinositide substrate (Lipsky & Leitman, 1982) . Although neomycin may not be a specific inhibitor of PLC activity, it has been demonstrated to be an effective inhibitor of phosphoinositide turnover (Tysnes et al., 1987) and not to inhibit phospholipid degradation by a phospholipase A2 mechanism or PC hydrolysis in dog kidney cells stimulated with a,-adrenergic agents . In contrast, the PA phosphohydrolase inhibitor propranolol does not inhibit thrombin-induced DAG formation. Propranolol abolishes DAG formation via the phospholipase D pathway in neutrophils stimulated with chemotactic peptide (Billah et al., 1989b) .
(iii) Finally, direct attempts to examine PC turnover by radiolabelling failed to detect formation of PA or phosphatidylethanol (a marker for phospholipase D activation) from PC, or release of choline metabolites. In neutrophils and HL60 granulocytes, 400 and 100% of the cellular PC turns over in response to chemotactic peptide (Billah et al., 1989b) or PMA stimulation (Billah et al., 1989a) respectively. This extent of PC hydrolysis should have been detected by the labelling strategies employed.
The conclusion that phosphoinositide hydrolysis is the primary source of agonist-stimulated DAG in platelets is consistent with previous observations. Broekman et al. (1981) found that PA formed in stimulated platelets has a fatty acid composition similar to that of the phosphoinositides, enriched in stearic and arachidonic acid. In addition, Muir & Murray (1988) found that phorbol esters (and thrombin) do not stimulate phosphate incorporation into PC in platelets (as they do in cell types where PC degradation is stimulated).
In contrast, Rubin (1988) PKC inhibitors resulted in a 2-4-fold over-production of DAG second messengers.
In contrast, Watson et al. (1988) observed no effect of staurosporine on inositol phosphate formation or on the formation of [32P]PA in thrombin-stimulated platelets. They concluded that the inhibition of PLC activity observed in cells treated with phorbol esters or cell-permeable DAG is not of physiological significance. Their results contrast with those reported here. We observed increased formation both of DAG mass and of [32P]PA in platelets treated with K252a. Since both DAG and InsP3 second messengers are rapidly metabolized, the ability to observe second-messenger over-production will depend on the time points chosen. Watson et al. (1988) measured inositol phosphate levels at 1 and 10 min after thrombin stimulation, and could have missed a transient over-production. Crouch & Lapetina (1989) reported that preincubation of platelets with 1 uM-staurosporine enhances the initial formation of [3Hlinositol-labelled InsP2 and InsP3 in thrombin-stimulated cells. King & Rittenhouse (1989) also observed increased inositol polyphosphate accumulation in staurosporine-treated platelets stimulated with thrombin for short time periods (10 s). They attributed this increase to blockade of PKC-mediated stimulation of InsP3 metabolism. Our finding that the lipid products of phosphoinositide hydrolysis are also over-produced argues strongly that PKC inhibitors also act to prevent negativefeedback regulation of this hydrolysis. The effect of K252a and staurosporine on platelet DAG levels does not appear to be due to inhibition of platelet DAG kinase. First, the time course of DAG formation and attenuation is similar in the presence or absence of PKC inhibitors. If platelets are treated with 1-mono-oleoylglycerol, an inhibitor of DAG kinase, DAG levels remain elevated after stimulation . Secondly, we found that K252a does not inhibit, but rather enhances, [32P] PA formation from endogenous DAG in thrombin-stimulated platelets. This is consistent with increased DAG formation leading to increased substrate availability for DAG kinase. Finally, in agreement with the findings of Watson et al. (1988) , we found that K252a and staurosporine do not inhibit phosphorylation of diC8 by unstimulated platelets. Surprisingly, K252a did decrease the rate of diC8 phosphorylation in thrombin-stimulated platelets. Since the rate of diC8 phosphorylation is similar in control and thrombin-stimulated platelets, this does not appear to be due to preventing PKC-mediated activation of DAG kinase. It is possible that the slower rate of diC8 phosphorylation in K252a-treated cells is due to the large increase in endogenous DAG formed in these cells acting as a competitive inhibitor with respect to diC8. MacDonald et al. (1988a) found that the rate of phosphorylation of a cell-permeant saturated DAG (didecanoylglycerol; diC10) was decreased in platelet-derived-growth-factor-stimnulated fibroblasts, owing to competition by the expanded pool of endogenous DAG (MacDonald et al., 1988a,b) .
In the present studies we have not ruled out a potential effect of PKC inhibitors on the DAG lipase pathway. Inhibition of DAG lipase is less likely to contribute to the observed DAG over-production, since this is a relatively minor pathway compared with DAG kinase . In addition, K252a and staurosporine are more likely to inhibit DAG kinase than DAG lipase, owing to the known mechanism of action of these compounds (e.g. Kase et al., 1987 Rhee et al., 1989) . Multiple forms of PLC are found in human platelets; their relation to the cloned forms remains to be resolved (Banno et al., 1988) . A PLC of 143 kDa was identified in platelet cytosol (Hakata et al., 1982 ), but appears to be immunologically distinct from the bovine brain forms of similar mass (Ryu et al., 1987) . Two forms of PLC have been resolved from human platelet membranes; one of these was identified as a 61 kDa protein (Banno et al., 1988) . The relationship of this protein to a 62 kDa form of the enzyme purified and cloned from guinea-pig uterus (Bennett & Crooke, 1987; Bennett et al., 1988) also remains to be determined. The latter enzyme is phosphorylated upon stimulation of rat basophilic leukaemia cells with phorbol esters, and is a substrate for PKC in vitro (Bennett & Crooke, 1987 (Crouch & Lapetina, 1988) or a novel G protein, G1 (Carlson et al., 1989) , may play an important role in thrombin- induced activation of PLC in platelets and that the a subunit of these G-proteins is phosphorylated in stimulated platelets.
Despite prevention of the negative-feedback role of PKC on phosphoinositide hydrolysis by using PKC inhibitors, DAG formation still reaches a peak at 0.5 min after stimulation and rapidly returns to basal levels. This indicates that additional mechanisms exist to desensitize thrombin-induced phosphoinositide hydrolysis. Crouch & Lapetina (1989) have provided evidence that platelet agonist receptors desensitize by two distinct mechanisms, one of which is independent of PKC. Paris et al. (1988) have provided evidence for PKC-independent homologous desensitization of thrombin receptors in hamster lung fibroblasts which appears to result from modification of the thrombin receptor, uncoupling it from its G-protein.
The potentiating effect of PKC inhibitors on phosphoinositide hydrolysis and second-messenger formation may have important consequences for the use of PKC inhibitors in intact cells. First, enhanced phosphoinositide hydrolysis may increase InsP3 levels and enhance the extent and duration of the Ca2+ signal (Crouch & Lapetina, 1988 . Secondly, over-production of DAG may modulate the activity of other membrane-associated enzymes. Candidates for DAG-modulated enzymes include phospholipase A2 (e.g. Kolesnick & Paley, 1987) and sphingomyelinase (Kolesnick, 1987) . DAG over-production also increases the available substrate for DAG lipase, an enzyme implicated in mobilization of arachidonic acid (Bell et al., 1979) . Therefore potentiation of the DAG signal may cause perturbations in pathways of lipid metabolism and signal transduction.
